Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pre-treated Relapsed or Refractory Multiple Myeloma
Teclistamab Data Featured as an Oral Presentation During ASCO Virtual Scientific Programme BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson…